The screening efficiency (i.e., number of HCC cases/1000 tests) for risk-stratified and precision surveillance were 18.4 and 18.3 cases/1000 tests, respectively in high-risk patients, higher than that of universal US + AFP (17.1 cases/1000 tests). The gene discussed is AFP; the disease is hepatocellular carcinoma.